China-based Frontier Biotechnologies Inc. (SHA: 688221) has entered into a partnership with compatriot firm Kindstar Global (HKG: 9960) to promote anti-infection diagnosis testing, with a particular focus on the HIV field. Financial details of the partnership were not disclosed.
Partnership Details
The collaboration aims to increase access to Frontier’s long-acting HIV fusion inhibitor albuvirtide (trade name: Aikening), which is China’s first homegrown innovative HIV therapy and the world’s first once-weekly HIV injection. The drug was approved in China in June 2018 for use as a two-drug regimen in treatment-experienced patients with HIV-1 replication.
Company Backgrounds
Founded in 2013, Frontier Biotechnologies offers a range of products including anti-coronavirus small-molecule drugs and anti-HIV long-acting combination therapies. Kindstar Global, on the other hand, is a large high-end medical specialty testing service group. Listed in Hong Kong in July of the previous year, Kindstar has a business presence covering over 3,000 hospitals in 600 cities across 31 provinces in China. Its services span hematology, neurology, oncology, genetics and rare diseases, women and children, cardiovascular, infectious diseases, rheumatology and immunology, ophthalmology, and more.-Fineline Info & Tech
